New combo pill aims to supercharge weight loss in obesity trial
NCT ID NCT07505303
First seen Apr 09, 2026 · Last updated Apr 30, 2026 · Updated 3 times
Summary
This study tests whether adding an experimental oral drug (ECC4703) to the existing weight-loss medication semaglutide helps adults with obesity lose more weight and reduce liver fat. About 160 participants will receive either the combination or a placebo for 20 weeks. The main goals are to measure changes in body weight and liver fat content using MRI.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WEIGHT MANAGEMENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AES - DRS - Optimal Research Florida - Melbourne
Melbourne, Florida, 32934, United States
-
AES - DRS - Synexus Clinical Research US, Inc. - Richfield - Minneapolis
Richfield, Minnesota, 55423, United States
-
AES - DRS - Synexus Clinical Research US, Inc. - San Antonio
San Antonio, Texas, 78229, United States
-
Anaheim Clinical Trials LLC - Anaheim - CenExel - PPDS
Anaheim, California, 92081, United States
-
Atlanta Center for Medical Research - CenExel ACMR - PPDS
Atlanta, Georgia, 30331, United States
-
Central Research Associates - Flourish - PPDS
Birmingham, Alabama, 35205, United States
-
Collaborative Neuroscience Network - Los Alamitos- CenExel - PPDS
Los Alamitos, California, 90720, United States
-
Flourish Research - San Antonio - PPDS
San Antonio, Texas, 78229, United States
-
ForCare Clinical Research - CenExel FCR - PPDS
Tampa, Florida, 33613, United States
-
Velocity Clinical Research (3345 N 107th St) - Omaha - Nebraska - PPDS
Omaha, Nebraska, 68134, United States
-
Velocity Clinical Research - Cincinnati (Springdale) - Ohio - PPDS
Cincinnati, Ohio, 45246, United States
-
Velocity Clinical Research - Dallas - PPDS
Dallas, Texas, 75230, United States
-
Velocity Clinical Research - Durham - PPDS
Durham, North Carolina, 27701, United States
-
Velocity Clinical Research - Providence - PPDS
East Greenwich, Rhode Island, 02818, United States
-
iResearch Atlanta - CenExel - PPDS
Decatur, Georgia, 30030, United States
Conditions
Explore the condition pages connected to this study.